Focus: Hidden - Minnesota

Filters close
Released: 17-Nov-2014 2:00 PM EST
Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma in Mayo Clinic-Led Study
Mayo Clinic

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.

14-Nov-2014 3:00 PM EST
Patients with Active Asthma at Higher Risk for Heart Attack, Mayo Clinic Research Shows
Mayo Clinic

Patients with active asthma — such as any use of asthma medications, and unscheduled office or emergency visits for asthma — are at a twofold risk of having a heart attack, according to Mayo Clinic research presented at the American Heart Association’s Scientific Sessions 2014.

14-Nov-2014 12:00 PM EST
Chemotherapy Following Radiation Treatment Slows Disease Progress and Improves Overall Survival in Adults with Low-Grade Brain Cancer
Mayo Clinic

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the Society for Neuro-Oncology’s 19th Annual Meeting in Miami by the study’s primary author Jan Buckner, M.D., deputy director, practice, at Mayo Clinic Cancer Center.

10-Nov-2014 10:00 AM EST
Blood Test Could Prevent Medication Trial and Error for Rheumatoid Arthritis Patients
Mayo Clinic

A molecule in the blood shows promise as a marker to predict whether individual rheumatoid arthritis patients are likely to benefit from biologic medications or other drugs should be tried, a Mayo Clinic-led study shows. The protein, analyzed in blood tests, may help avoid trial and error with medications, sparing patients treatment delays and unnecessary side effects and expense. The research is among several Mayo Clinic studies presented at the American College of Rheumatology annual meeting in Boston.

Released: 14-Nov-2014 4:25 PM EST
Mayo Clinic Trustees Welcome New Board Member
Mayo Clinic

The Mayo Clinic Board of Trustees welcomed Mary Sue Coleman, Ph.D., as a new public member at its quarterly meeting today.

5-Nov-2014 4:55 PM EST
Study: Vitamin B May Not Reduce Risk of Memory Loss
American Academy of Neurology (AAN)

Taking vitamin B12 and folic acid supplements may not reduce the risk of memory and thinking problems after all, according to a new study published in the November 12, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the largest to date to test long-term use of supplements and thinking and memory skills.

Released: 11-Nov-2014 3:45 PM EST
Chromosomal Rearrangements Help Distinguish Between Independent Primary Tumors and Metastasis
Mayo Clinic

A diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung, a Mayo Clinic study has found.

Released: 10-Nov-2014 9:00 AM EST
Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer
Mayo Clinic

Researchers at Mayo Clinic’s campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.

Released: 10-Nov-2014 8:00 AM EST
Combination Therapy Offers Quicker, Less Toxic Eradication of Hepatitis C in Liver Transplant Patients
Mayo Clinic

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

Released: 4-Nov-2014 12:00 PM EST
Mayo Clinic Researchers Discover Genetic Markers for Alcoholism Recovery
Mayo Clinic

In an international study, Mayo Clinic researchers and collaborators have identified genetic markers that may help in identifying individuals who could benefit from the alcoholism treatment drug acamprosate. The findings, published in the journal Translational Psychiatry, show that patients carrying these genetic variants have longer periods of abstinence during the first three months of acamprosate treatment.



close
1.14924